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ORIGINAL ARTICLE
Background: During the period that randomized clinical trials were 
establishing the role of adjuvant therapy in tumors larger than 5 
cm without lymph-node invasion, which shifted from stage IB (6th 
TNM) to stage II (7th TNM), we derived the rate of shifted patients 
in our series and analyzed the relationship between specific patient- 
and tumor- characteristics, and clinical outcome, to identify putative 
prognostic factors.
Methods: We retrospectively collected data (age, sex, smoking 
status, type of surgery grading, and histological type) from 467 
patients who underwent radical surgery for primary 6th TNM-T2N0 
non–small cell lung cancer patients between 1998 and 2009 at our 
institute. Categorical variables were cross-tabulated by tumor stag-
ing according to the 7th TNM edition, and they were tested both for 
association with stage and survival.
Results: One hundred and eighteen patients shifted to stage II, 
mainly older patients and patients with a sarcomatoid or a poorly 
differentiated carcinoma. Median overall survival time was signifi-
cantly different across stages. Among the factors investigated, only 
the tumor dimension resulted in being statistically significant in mul-
tivariate analysis.
Conclusions: Nearly a quarter of patients shifted from stage I (6th 
TNM) to stage II (7th TNM), raising a major need for information on 
the effects of adjuvant chemotherapy in this group of patients. Our 
findings suggest that randomized clinical trials aimed at addressing 
this topic should consider only tumor dimensions as principal selec-
tion criteria.
(J Thorac Oncol. 2012;2012;7: 1124–1130)
In the 7th edition of the Tumor, Node, Metastasis (TNM) classification, pN0 non–small-cell lung cancer patients 
(NSCLC) with primary tumor dimension larger than 5 cm 
shifted from stage IB to stage IIA (>5 but ≤ 7 cm) or stage 
IIB (>7 cm), because of a poorer prognosis of these patients 
compared to those with smaller pN0 tumors. This shift raises 
many issues concerning the management of this subpopula-
tion of patients, particularly in terms of adjuvant chemother-
apy.1 Indeed, adjuvant chemotherapy is provided as a standard 
treatment by international guidelines for patients with stage 
II NSCLC. However, this statement is based on the 6th TNM 
edition, founded mainly on data coming from T1–T2 N1 
patients.2–5
On the contrary, there is a lack of definitive information 
concerning the effect of adjuvant chemotherapy in patients 
with newly classified stage II pN0 NSCLC, although its ben-
efit could be expected according to their poorer prognosis 
and to data coming from the Cancer and Leukemia Group B 
9633 phase III randomized trial, which showed a significant 
advantage in overall survival (OS) and disease-free survival 
in the subgroup of NSCLC patients with tumors greater-
than 4 cm treated with adjuvant paclitaxel and carboplatin 
combination.6
To design trials addressing the clinical issues raised by 
the 7th TNM, a thorough knowledge of this newly staged sub-
set of patients and tumors is needed. In this study, we analyzed 
the data from all patients who underwent surgery with radical 
lymphadenectomy for primary 6th TNM- T2N0 NSCLC at our 
institute between 1998 and 2009.
The aim of this analysis was to assess the rate of patients 
who shifted from stage IB (6th TNM) to stage IIA/B (7th 
TNM), and to describe specific characteristics of this subpop-
ulation compared to patients with smaller T2N0 NSCLC.
Moreover, we analyzed the clinical outcome of shifted 
patients to assess whether the worse prognosis observed in 
patients with tumors larger then 5 cm is confirmed in the sub-
set of patients from our series who were accurately staged 
with a clinical workup including positron emission tomogra-
phy (PET) scan and a surgical anatomic resection with radi-
cal lymphadenectomy. Finally, we analyzed the relationship 
between biological characteristics and clinical outcome of 
these patients, to find out putative prognostic factors. Indeed, 
the identification of negative prognostic factors could be 
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helpful in the design of clinical trials to establish the role of 
adjuvant chemotherapy, which is completely unknown at the 




We retrospectively analyzed demographic and tumor-
related data (age, sex, smoking status, type of surgery, grad-
ing, and histological type) of patients with a stage Ib (6th 
TNM) NSCLC who underwent resection at the European 
Institute of Oncology of Milan between 1998 and 2009. The 
criteria required for inclusion in this analysis were radical 
surgery with systemic lymphadenectomy and diagnosis of a 
pathologic T2N0 NSCLC. Patients previously treated with 
induction chemo and/or radiation therapy were excluded from 
the study population analysis, and also patients having tumors 
with microscopic (R1) and macroscopic (R2) residual disease. 
Routine preoperative workup included pulmonary functional 
tests and chest and abdomen ± brain computed tomography 
scan plus PET scan to study the extension of the local disease 
and exclude the presence of distant metastases.
Tumor specimens were diagnosed by a lung cancer ref-
erent pathologist, and staged according to 6th TNM. Survival 
data were obtained directly from the patient or through family 
contact or, in the cases in which this was not possible, from the 
local registry office services. Data dealing with patient hab-
its, such as the smoking status, came from physician notes. 
Former smokers were considered individuals who had smoked 
at least 100 cigarettes in his/her lifetime and had quit more 
than 12 months earlier.
The histologic grade of differentiation (G1, well differ-
entiated; G2, moderately differentiated; and G3, poorly dif-
ferentiated) and the histological subtypes were not reviewed 
case by case but were obtained through pathology reports. 
However, we have to state that the pool of lung cancer referent 
pathologists has not varied substantially across the years. All 
patients gave their informed consent for the utilization of data 
for scientific purposes.
Statistical Methods
Patients’ characteristics were tabulated and summarized 
using counts and percentage. Frequency distribution of prog-
nostic factors across TNM categories were compared using 
either Fisher’s exact test or χ2 test as appropriate. Age at sur-
gery for patients who shifted to stage II was tested against Ib 
patients using the unpaired t test, and follow-up times were 
compared using the Kruskal-Wallis test because of their non-
normality (Shapiro-Wilk test). For the sake of comparison with 
International Association for the Study of Lung Cancer Lung 
Cancer Staging Project age at surgery was also categorized 
using a cutpoint of 70 years. OS was defined as the time from 
the date of surgery until death from any cause and estimated by 
the Kaplan-Meier method, and the between-group comparisons 
were done using the log-rank test. Univariate and multivariate 
Cox proportional hazards model was used to estimate the crude 
and adjusted hazard ratios (HR) for the following risk factors: 
age at surgery, sex, smoking status, type of surgery, grading, 
and histology. Both median OS and HR have been tabulated 
alongside their 95% confidence intervals. All tests were two-
sided and considered statistically significant at the 5% level. All 
analyses were conducted using SAS 9.2 software (Cary, NC).
RESULTS
Patient and Tumor Characteristics
We included in our study 467 patients diagnosed with 
a pathologic T2N0 (stage IB according to the 6th TNM) 
NSCLC between 1998 and 2009. This category comprised 
tumors larger than 3 cm without lymph-node metastasis and 
tumors that invaded the visceral pleura or were located at the 
hilar region.
One hundred and four patients (22%) were women and 
363 (78%) were men. The median age was 68 years (range, 
39–88). Of the 441 patients with known smoking history, 51 
(12%) were never smokers, 257 (64%) were former smokers, 
and 133 (33%) were still smoking. The surgical procedure 
was a minor parenchymal volume resection (MPVR) in 429 
patients (92%; 86% lobectomy, 6% other typical resection), 
a bilobectomy in 15 patients (3%), and a standard pneumo-
nectomy in 23 patients (5%). All patients underwent a radical 
lymphadenectomy. Of the resected tumors, 273 (58%) were 
adenocarcinoma, 152 (33%) squamous cell carcinoma, 17 
(4%) adenosquamous carcinoma, and 25 (5%) were highly 
aggressive tumors such as large-cell carcinoma (eight), undif-
ferentiated carcinomas (one), and sarcomatoid carcinoma 
(16). Fifty-three patients (11%) had a well-differentiated G1, 
157 (34%) a moderately differentiated G2, and 257 (55%) a 
poorly differentiated G3 carcinoma. Patient and tumor charac-
teristics are summarized in Table 1.
Features of Large Node-Negative Tumors 
Shifted to Stage II
Among all the T2N0 patients, we selected those with 
tumors larger than 5 cm that shifted to stage II in the 7th TNM 
classification. We observed that 118 patients (26%), out of 
467, shifted from stage IB (6th TNM) to stage II (7th TNM): 
87 (19%) to stage IIA (T2b: >5 but ≤7) and 31 (7%) to stage 
IIB (T3: >7 cm) (Fig. 1).
A comparison of the demographics and clinical char-
acteristics of the shifters with those of not-shifted patients 
showed that there were no differences regarding the distribu-
tion of sex (p = 0.412) and smoking status (p = 0.788) (Table 
2). On the contrary, patients classified as stage IIB were on 
average 2.7 years significantly older than patients not shifted 
(p = 0.039) and 4.2 years older than patients shifted to stage 
IIA (p = 0.013) (Supplementary Table, Supplemental Digital 
Content, http://links.lww.com/JTO/A291).
Analysis of the histopathological tumor features showed 
that sarcomatoid carcinomas (p = 0.015) and high-grade tumors 
(p = 0.010) shifted more often than others to stage IIB (Table 
2). Characteristics of these populations are reported in Table 2.
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Survival Analysis
The Kaplan-Meier curves in Figure 2 show OS in 
relation to pathologic stage calculated with the 7th TNM 
classification.
The median survival time was significantly different 
across TNM categories (p = 0.010). The pairwise comparisons 
revealed that the most striking difference was between stage IB 
(112.0 months) versus IIB (45.2 months, p = 0.003). Stage IIA 
had a smaller yet significant difference compared to stage IB 
(median survival time = 54.6 months, p = 0.028) (Table 3).
Five-years’ survival rate was 47.7%, 47.4%, and 71.2% 
for stage IIA, IIB, and IB, respectively (Table 3).
Median follow-up was not significantly different among 
patients shifted versus not-shifted (39.3 months, 41.5 months, 
and 47.0 months for stage IIA, IIB, and IB, respectively [p = 
0.689]), suggesting that differences in observed survival was 
not biased by different follow-up lengths.
Prognostic Factors of the T2N0 (6th TNM) 
Population
In addition to the TNM category, age, sex, smoking 
status, type of surgery, grading, and histological type were 
investigated as prognostic factors in the whole T2N0 (6th 
TNM) population. Among these variables, the multivariate 
analysis confirmed the TNM as the main prognostic factor 
(IIB versus IB, HR = 1.90, p = 0.036) and suggested age as 
another important factor (HR = 1.76. p = 0.002 for age >70 
years) (Table 4).
Prognostic Factors of T2N0 Non-Shifted 
Patients
Subgroup (e.g., within strata) analysis were also per-
formed to find out negative prognostic factors within the group 
of 349 patients belonging to T2N0 (6th TNM) who did not shift 
to stage IIA or IIB (7th TNM). No statistically significant factors 
emerged from the univariate and multivariate analysis. It was 
observed that patients undergoing MPR had a better prognosis 
as compared to patients undergoing bilobectomy (MPR versus 
bilobectomy HR = 0.33, p = 0.008) (Table 5). However, only 
few patients (eight cases) were included in the latter category.
Prognostic Factors of Patients with Large 
Node-Negative Tumors Shifted to Stage II
A further subgroup analysis was performed for the 
group of patients initially belonging to the T2N0 (6th TNM) 
and shifted to the stage IIA or IIB for the dimension larger 
than 5 cm. Among the set of the prognostic factors previously 
investigated, age was the only significant variable associ-
ated with survival, both in univariate and multivariate analy-
sis (Table 6 and Supplementary Table, Supplemental Digital 
Content, http://links.lww.com/JTO/A291).
DISCUSSION
This study focused on the “new” staged population who 
shifted from stage I to stage II according to the 7th TNM edi-
tion in lung cancer.
TABLE 1. Patient and Tumor Characteristics
Characteristic Overall No. (%)
No. of patients 467
Median age 68 (range 39–88)
Sex
 Male 363 (78)
 Female 104 (22)
Smoking statusa
 Past 257 (64)
 Current 133 (33)
 Never 51 (12)
Surgery
 MPRV 429 (92)
 Bilobectomy 15 (3)
 Pneumonectomy 23 (5)
Histological type
 Adenocarcinoma 273 (58)
 Squamous cellular 152 (33)
 Large-cell 8 (2)
 Undifferentiated 1 (0)
 Sarcomatoid 16 (3)
 Adenosquamous 17 (4)
Grading
 G1 53 (11)
 G2 157 (34)
 G3 257 (55)
a Status was not specified for 26 patients (6%).
MPRV, minor parenchymal resection volume.
FIGURE 1.  Proportion of T2N0 (6th TNM) shifted to 
stage II (7th TNM). TNM, tumor, node, metastasis.
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We retrospectively analyzed 467 patients staged as 
pT2N0 with the 6th TNM and found that nearly a quarter of 
the entire population (118 patients, 26%) was reclassified as 
stage II, according to the 7th TNM, because of tumor dimen-
sions larger than 5 cm (Fig. 1). This new stage II population 
comprises a large number of people and therefore justifies 
specific studies aimed at better characterizing this subset of 
patients. Indeed, the identification of prognostic factors could 
be helpful for clinicians to design clinical trials investigating 
the best therapeutic strategies for large node-negative tumors.
We first investigated the clinical and histopathological 
features of the patients who shifted to stage II. We observed that 
these patients were significantly older and had a higher per-
centage of high-grade or highly aggressive tumors compared 
to those not shifted (Table 2). Possible explanations for the 
different ages between the two groups could be an occasional 
sample selection in our case series or a center effect, resulting 
in a possible confounding effect for stage IIB. Nevertheless, 
the higher proliferation rate, typically featured by poorly dif-
ferentiated and highly aggressive tumors such as sarcomatoid 
and large-cell carcinomas, could certainly explain the larger 
dimensions observed for stage II cancers.
With regard to the OS, the T descriptor emerged as a 
main prognostic factor in multivariate analysis (Table 4). 
The lack of significance between stage IIA and IIB (p = 
TABLE 3. Overall Survival Kaplan-Meier Estimates with 
5-Years Survival Rate
Staging




IB 103 (29.5) 112.0 (80.7, —) 71.2
IIA 33 (37.9) 54.6 (51.6, —) 47.7
IIB 14 (45.2) 45.2 (20.9, —) 47.4
Log-rank: overall comparison p = 0.010; pairwise comparisons: IIA vs. IIB p = 
0.926; IIA vs. IB p = 0.028; IIB vs. IB p = 0.003
FIGURE 2. Overall survival curves by pathologic stage 
according to 7th TNM classification. TNM, tumor, node, 
metastasis.
TABLE 2. Characteristics of the Large Node-Negative Tumors Shifted to Stage II
Characteristic
Staging No. (column %)
IIA (N = 87) IIB (N = 31) IB (N = 348) p Valuea
Age (yrs)
 <70 59 (67.8) 13 (41.9) 222 (63.8) 0.032
 ≥70 28 (32.2) 18 (58.1) 126 (36.2)
Sex
 Female 21 (24.1) 4 (12.9) 79 (22.6) 0.412
 Male 66 (75.9) 27 (87.1) 270 (77.4)
Smoking status
 Former 53 (60.9) 20 (64.5) 184 (52.7)
 Current 20 (23.0) 8 (25.8) 105 (30.1) 0.788
 Never 9 (10.3) 2 (6.5) 40 (11.5)
 Not specified 5 (5.8) 1 (3.2) 20 (5.7)
Histology
 Adenocarcinoma 48 (55.2) 13 (41.9) 212 (60.7)
 Squamocellular 31 (35.6) 13 (41.9) 108 (31.0)
 Large-cell carcinoma 4 (4.6) 1 (3.2) 3 (0.9) 0.015
 Undifferentiated 0 0 1 (0.3)
 Sarcomatoid 3 (3.5) 4 (12.9) 9 (2.6)
 Adenosquamous 1 (1.2) 0 16 (4.6)
Grading
 G1 9 (10.3) 1 (3.2) 43 (12.3)
 G2 18 (20.7) 9 (29.0) 130 (37.2) 0.010
 G3 60 (69.0) 21 (67.7) 176 (50.4)
a χ2 or two-sided Fisher’s exact test as appropriate.
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TABLE 4.  Univariate and Multivariate Cox Proportional Hazards for T2N0 (6th TNM)
Risk Factor Median OS moa (95% CI) Unadjusted HR (95% CI) p Value Adjusted HR (95% CI) p Value
TNM category
 IB (T2aN0) 112.0 (80.7, —) Reference Reference
 IIA (T2bN0) 54.6 (50.9, —) 1.52 (1.01, 2.28) 0.044 1.46 (0.95, 2.24) 0.083
 IIB (T3N0) 45.2 (20.9, —) 2.43 (1.38, 4.26) 0.002 1.90 (1.04, 3.48) 0.036
Age at Surgery
 <70 Not reached Reference Reference
 ≥70 73.3 (58.9, 91.2) 1.64 (1.17, 2.29) 0.004 1.76 (1.23, 2.51) 0.002
Sex
 Female Not reached Reference Reference
 Male 99.8 (75.7, 124.4) 1.74 (1.11, 2.72) 0.016 1.50 (0.94, 2.41) 0.091
Smoking Status
 Never Not reached Reference Reference
 Former 99.8 (75.7, —) 1.98 (1.00, 3.94) 0.051 1.45 (0.70, 3.00) 0.322
 Current 77.4 (58.5, —) 1.82 (0.89, 3.74) 0.101 1.61 (0.75, 3.46) 0.219
Surgery
 Bilobectomy 62.0 (25.9, —) Reference Reference
 MPVR 104.5 (79.5, —) 0.73 (0.34, 1.57) 0.423 0.77 (0.34, 1.74) 0.529
 Pneumonect. 69.6 (28.8, —) 1.17 (0.45, 3.08) 0.749 1.00 (0.38, 2.65) 0.998
Grading
 G1 Not reached Reference Reference
 G2 112.0 (77.4, —) 1.22 (0.65, 2.29) 0.539 1.07 (0.55, 2.08) 0.842
 G3 79.5 (63.0, 124.4) 1.81 (1.01, 3.06) 0.047 1.28 (0.66, 2.47) 0.459
Histology
 Adenocarcinoma 115.8 (77.7, —) Reference Reference
 Squamous 99.8 (62.0, —) 1.43 (1.00, 2.05) 0.049 1.06 (0.71, 1.58) 0.785
 Other 69.2 (45.2, —) 1.92 (1.11, 3.32) 0.019 1.42 (0.79, 2.55) 0.240
a  Median overall survival from Kaplan-Meier estimate.
MPVR, minor parenchymal volume resection; CI, confidence interval; HR, hazard ratio; TNM, tumor, node, metastasis.
TABLE 5.  Univariate and Multivariate Cox Proportional Hazards for Non-Shifters Only
Risk Factor Median OS moa (95% CI) Univariate HR (95% CI) p Value Multivariate HR (95% CI) p Value
Age at Surgery
 <70 124.4 (87.3, —) Reference Reference
 ≥70 81.5 (69.2, 112.0) 1.43 (0.97, 2.11) 0.074 1.33 (0.87, 2.03) 0.192
Sex
 Female Not reached Reference Reference
 Male 112.0 (78.3, —) 1.55 (0.92, 2.61) 0.098 1.56 (0.88, 2.77) 0.127
Smoking status
 Never 53.3 (35.2, —) Reference Reference
 Former 104.5 (75.7, —) 2.50 (1.08, 5.79) 0.032 1.84 (0.75, 4.51) 0.180
 Current 87.3 (63.0, —) 1.89 (0.78, 4.58) 0.160 1.58 (0.60, 4.13) 0.351
Surgery
 Bilobectomy 43.1 (20.7, —) Reference Reference
 MPVR 115.1 (81.5, —) 0.33 (0.14, 0.75) 0.008 0.31 (0.13, 0.75) 0.009
 Pneumonect. Not reached 0.17 (0.02, 1.43) 0.103 0.13 (0.02, 1.13) 0.065
Grading
 G1 Not reached Reference Reference
 G2 112.0 (77.4, —) 1.20 (0.61, 2.36) 0.606 0.80 (0.37, 1.72) 0.569
 G3 104.5 (73.3, 124.4) 1.57 (0.82, 3.00) 0.170 1.07 (0.49, 2.35) 0.868
Histology
 Adenocarcinoma 115.8 (81.5, —) Reference Reference
 Squamous 104.5 (69.6, —) 1.41 (0.94, 2.13) 0.101 1.32 (0.82, 2.12) 0.261
 Other 124.4 (33.2, —) 1.77 (0.90, 3.48) 0.099 1.76 (0.85, 3.65) 0.128
a  Median overall survival from Kaplan-Meier estimate.
MPVR, minor parenchymal volume resection; CI, confidence interval; HR, hazard ratio.
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0.083) could be because of the overlapping of the curves 
and the small number of cases left at 60 months in IIB stage 
population. However, a difference in prognosis is evident 
from the Kaplan-Meier survival curves that decline more 
rapidly for patients in stage IIB as compared to stage IIA 
patients, and from the median of the OS that decreases from 
112 months to 54.6 and 45.2 for IB, IIA and IIB, respec-
tively (Table 3).
Of interest, our data coming from “true” T2N0 dis-
eases are consistent with those widely highlighted by the 
International Association for the Study of Lung Cancer Lung 
Cancer Staging Project derived from an heterogeneously staged 
population.7 Indeed, all the patients enrolled in our study have 
been accurately staged with a clinical workup including PET 
scan and radical surgeries associated to a systemic lymph-
adenectomy. These selection criteria acted as a guarantee of 
the correct staging of the tumor8 and avoided N1-N2 disease 
stage misdiagnoses.
At present, there is a lack of definitive information on 
the effect of adjuvant chemotherapy in patients with large 
node-negative NSCLC shifted to stage II. As a consequence, 
the major aim of the study was to increase knowledge about 
the prognostic factors in this subset of patients to better inform 
oncologists who are challenged with the topic of adjuvant che-
motherapy in patients who have shifted from stage IB (6th 
TNM) to stage II (7th TNM).
Therefore, we analyzed patients’ survival according to 
age, sex, smoking status, type of surgery, histological type, 
and grading both in non-shifted (Table 5) and in large node-
negative shifted tumors (Table 6). None of the variables 
investigated were found to be significantly associated with 
a poorer prognosis in the subgroup analysis performed. In 
fact, the finding of a better prognosis observed in non-shifted 
patients undergoing MPR as compared to those undergoing 
bilobectomy is hampered by the few available bilobectomies.
In conclusion, more than a quarter of patients with a 
T2N0 NSCLC (6th TNM) shifted from stage T2N0 (6th TNM) 
to stage II (7th TNM), emphasizing the need for information 
concerning the role of adjuvant chemotherapy in this subgroup 
of large node-negative tumors with poor prognosis.
Our data suggest that randomized clinical trials aimed at 
addressing this topic should consider only tumor dimensions 
and not other variables such as age, sex, smoking status, type 
of surgery, histological type, and grading as principal selec-
tion criteria.
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